Report: Pfizer may make a bid for Protalix

Israel's Protalix BioTherapeutics (PLX) has seen its shares skyrocket 415 percent this year. And its success developing a new Gaucher disease therapy appears to have attracted some intense interest from Pfizer.

Reporters at TheMarker say that a delegation from Pfizer visited Protalix's facilities in Israel in anticipation of a development deal and possible buyout. Protalix Chief Executive David Aviezer has already said he expects to have a pact in place by the end of this year. The company has made waves in the Gaucher disease market with a successful late-stage trial of Uplyso. A likely contender to Cerezyme, the drug is being readied for an NDA after Genzyme announced problems with contamination at the facility that makes its extraordinarily expensive drug.

- read the report from Reuters

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.